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Abstract 
The activation of protein kinase C (PKC) is irreversibly regulated by limited proteolysis catalyzed by a calcium-activated neutral 
cysteine protease, calpain. Calpain cleaves PKC a at specific sites in the hinge region between the catalytic and the regulatory domains of 
this kinase. Here we show a novel method for production of antibodies that bind specifically to the catalytic fragment of PKC a but not to 
the unproteolyzed protein. To detect proteolyzed PKC tr 'cleavage site-directed antibodies,' which recognize amino-terminal regions in 
the nascent catalytic fragments and do not cross-react with the unproteolyzed enzymes, were raised using synthetic peptides 
corresponding to the amino-terminal sequences. The synthetic peptides used in this study were the sequences of human PKC a at the 
cleavage sites by m- and /x-types of calpains (LGPAGNKV and VISPSEDRKQPSNNLDRVKLT, respectively) and they are designated 
as CFcz 2, CFa4, in this order. Each synthetic peptide was injected into rabbit after conjugation with a carrier protein. The antibodies thus 
obtained (anti-CFa2 or -CFo;4) specifically reacted with either the 46- or 45-kDa catalytic fragment of PKC a, respectively, whereas 
they did not cross-react with other fragments. Furthermore, the antibodies did not bind to the unproteolyzed nzyme nor fragments of 
PKCa obtained by treatment with other proteinases unless the fragment carried the same amino-terminal sequence. When human 
platelets were treated with calcium ionophore, the catalytic fragments of PKC a (45- and 46-kDa) were detected in the cytosol by 
immunoblotting with the antibodies. However, these antibodies did not bind unproteolyzed 80-kDa PKC a, although this form was 
dominant in the cytosol of the calcium ionophore-treated human platelets. In addition, the 45-kDa catalytic fragment of PKC a was 
detected in an apoptotic human fibroblast TIG-3 cells cultured in serum-free medium. Our method is applicable for analysis of proteolysis 
in various cellular states. 
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1. Introduction 
Protein kinase C (PKC 1) is involved in many cellular 
functions including secretion, endocytosis, proliferation and 
differentiation [1-3]. The activity and location of PKC are 
regulated by Ca 2+ and phospholipids. When intracellular 
Ca 2+ concentration increases, cytosolic PKC associates 
with membranes and phosphorylates substrates present in 
the membranes. Translocation of PKC is also observed 
when cells are treated with tumor-promoting phorbol esters 
[4-6]. The membrane-bound PKC is known to be cleaved 
at a specific site by calpain (Ca2+-activated neutral pro- 
tease; EC 3.4.22. 17) [7] or trypsin-like membrane protease 
Abbreviations: PKC, protein kinase C; KLH, keyhole lympet hemo- 
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[8], and then released to cytosol [9]. Through this limited 
proteolysis, PKC loses its amino-terminal regulatory re- 
gion and exhibits its kinase activity without Ca 2÷ and 
phospholipids. The catalytic fragment of PKC thus gener- 
ated is considered to phosphorylate cytosolic substrates 
[10,11]. On the other hand, limited proteolysis of PKC is 
also thought o be an initial step for down-regulation of 
this enzyme [10,12], since the catalytic fragment is unsta- 
ble and degraded further in cells. To investigate intra- 
cellular proteolysis of PKC, a cleavage site-directed anti- 
body that discriminates the proteolyzed form of enzymes is 
a powerful tool for in situ analyses of enzyme regulation 
mediated by proteolysis. 
We have reported evelopment of such antibodies which 
specifically reacts with the amino-terminal region of the 
catalytic fragment of PKC/3 generated by calpain-cata- 
lyzed limited proteolysis but not with unproteolyzed en- 
zymes, and an active form of calpain lacking amino-termi- 
nal pro-peptide [13,14]. In this paper, procedures for prepa- 
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ration of cleavage site-directed antibodies are described for 
the catalytic fragments of PKC a cleaved by calpain. 
2. Experimental procedures 
Materials. The following reagents used were obtained 
from the following sources: Keyhole lympet hemocyanin 
(KLH), trypsin and a-chymotrypsin were from Sigma; 
epoxy-activated Sepharose 6B from Pharmacia-LKB; poly- 
vinylidene difluoride (PVDF) membranes from Millipore; 
BA83 nitrocellulose filter from Schleicher and Schuell. 
Secondary antibodies for detection of antigens on immuno- 
blotting filters were anti-rabbit IgG (goat IgG) conjugated 
with alkaline phosphatase from Promega, and anti-rabbit 
IgG (goat IgG) conjugated with horseradish peroxidase 
from IBL (Gumma, Japan). Human PKCs were prepared 
from platelets by DE52 and threonine-Sepharose chro- 
matography according to the method escribed by Kikkawa 
et al. [15]. The mixture of PKC isozymes (a  and fl) were 
further fractionated by a hydroxyapatite column (Tonen) 
joined to a Pharmacia FPLC system [16]. High- and Iow- 
Ca2+-requiring calpains (m- and /z-types) were prepared 
from human placenta nd human erythrocytes, respectively 
[17]. 
Cells. TIG-3 cells (JCRB506) were supplied by Japan 
Cancer Cell Research Bank, and were grown in Dulbecco's 
Modified Eagle's Medium (DMEM; Nissui) supplemented 
with 10% fetal bovine serum, 2 mM glutamine, penicillin 
G (100U/ml), and streptomycin (200/xg/ml)  at 37°C in a 
humidified atmosphere of 5% CO 2, 95% air. Human 
platelets were obtained from healthy donors. 
Peptide synthes& and antibody preparation. Peptides 
were synthesized by the solid phase method with an 
Applied Biosystems Model 430A peptide synthesizer and 
purified by reverse-phase high performance liquid chro- 
matography on C18 column [13]. Fig. 1 shows the amino 
acid sequences of PKCa in the V3 regions between the 
catalytic and regulatory domains. Cleavage sites of PKC a 
by calpain were established by Kishimoto et al. for rat 
PKCo~ [18]. Calpains /.L and m preferably cleave the 
carboxyl terminal sides of Lys-Val and Lys-Leu, respec- 
tively. As the amino acid sequences around this region of 
PKC a are highly conserved among animals [19], calpains 
may catalyze the same sites for human PKCa.  For the 
haptens for cleavage site-directed antibodies, we synthe- 
sized peptides corresponding to the newly appeared 
amino-terminal region of the proteolyzed PKC a (CFa 1 to 
4). Carboxyl-terminal region of PKCa (CTa ,  
(C)DQSDFEGFSYVNPQFVHPILQSAV; res. 649-672) 
was synthesized with the amino-terminal Cys to detect 
both catalytic fragments and unproteolyzed enzymes at the 
same time in immunoblotting assays. Peptides were conju- 
gated with KLH and used as immunogens. For the assay of 
antibodies, peptides V3 a l ; res. 305-317 and V3a 2; res. 
310-337) were also synthesized. In each peptide xcept for 
CTa, a cysteine residue was added at the carboxyl-terminus 
for conjugating with carrier protein or epoxy-activated 
Sepharose 6B, with the a-amino group in the peptides 
free. Peptide-KLH conjugates used for immunization and 
peptide-bovine s rum albumin (BSA) conjugates used for 
assay of antibody were prepared as described by Liu et al. 
[20]. Immunization was performed as described before 
[13]. Antibodies were purified by affinity chromatography 
on immobilized peptides. Two milliliter of the antiserum 
was incubated with 0.75 ml bed volume of peptide-con- 
jugated Sepharose 6B for 1 h at 4°C. The resin was washed 
with 10 ml of Tris-buffered saline (TBS, 20 mM Tris-HC1 
(pH 7.5), 150 mM NaC1), and the antibodies bound to the 
resin were eluted with 2 bed volumes of 0.1 M Glycine-HCl 
Regulatory Domain Catalytic Domain 
V1 C1 V2 C2 V3 C3 V4 C4 V5 
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• 
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Fig. 1. Structures ofhuman PKC a and peptides used as immunogens. The structure ofhuman PKC a is shown schematically, where the conserved and 
divergent regions among isozymes are indicated as C and V, respectively [3]. The amino acid sequences of the V3 region are indicated in one-letter 
abbreviations [19]. Cleavage sites for human PKC by calpain m (v) or Iz (•)  were deduced from those in rat PKC determined byKishimoto et al. [18]. 
Synthetic peptides corresponding to the V3 region used in this study are indicated. 
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(pH 2.5). To the eluate was added 0.05 volume of 1 M Tris 
solution containing 40 mg/ml BSA. Concentrations of 
antibodies thus purified were 20-400 /~g/ml. 
Dot blot assay. One microliter of peptide-BSA conju- 
gate (corresponding to 100 ng peptide) was spotted on a 
nitrocellulose filter. The filter was washed with TBS, 
shaken in 20 mg/ml BSA in TBS for 30 min, and finally 
washed with TBS. Affinity-purified antibody was diluted 
sequentially with TBS containing 20 mg/ml BSA, and 
incubated for 2 h at 37°C with the antigen-spotted filters 
thus prepared. After the incubation, the filter was washed 
with TBS containing 0.0:5% (w/v)  Tween 20 and incu- 
bated with horseradish peroxidase-conjugated antibody 
(anti-rabbit IgG, 1 /zg/ml in TBS containing 20 mg/ml 
BSA). Binding of antibodies was visualized by color de- 
velopment with peroxidz.se using 3,3'-diaminobenzidine 
and hydrogen peroxide as substrates. 
lmmunoblot assay. Purified PKCa was digested by 
calpains, trypsin or chymotrypsin as described previously 
[13]. Fragments of PKC a were first characterized by 
immunoblotting using antibodies raised against the car- 
boxyl-terminal regions of PKC a (anti-CTa). Proteolyzed 
PKC a was subjected to SDS-PAGE and electrotransferred 
onto PVDF membranes. The protein-transferred PVDF 
membranes were immersed in a 20 mg/ml BSA solution 
in TBS, and then incubated with antibodies (0.1-0.5 
/zg/ml) overnight at 4°C. Antibody bindings were colori- 
metrically visualized by anti-rabbit IgG conjugated with 
alkaline phosphatase, using 5-bromo-4-chloro-3-in- 
dolylphosphate asa substrate. 
Calcium ionophore A23187-treatment of human 
platelets. Human platelets were suspended in Hanks' bal- 
anced salt solution (pH 7.4) containing 0.1% BSA. 
Ionophore A23187 (5 /xM) was added to the cell suspen- 
sion, and the mixture was incubated at room temperature 
for 2-5 min. The samples for SDS-PAGE were prepared 
as described previously [ 13,21 ]. 
Serum-free treatment of TIG-3 cells. TIG-3 fibroblasts 
were cultured in DMEM with 10% fetal bovine serum, and 
culture media were changed to serum-free medium, and 
then incubated for 48 h. The cells were treated with 10% 
trichioroacetic acid (TCA), recovered from the culture 
flask with a rubber policeman, and collected by centrifuga- 
tion. The TCA-treated cells were dissolved in 0.5 M 
Tris-HCl (pH 6.8) containing 2% (w/v) lithium dodecyl 
sulfate, 6% (w/v)  glycerol, and 5% (w/v)  2-mercapto- 
ethanol, and heated at 100°C for 5 min. The samples were 
subjected to SDS-PAGE followed by immunoblotting. 
DNA fragmentation analysis was performed as follows. 
Serum-free terated TIG-3 cells were lysed with 50 mM 
Tris-HCl buffer (pH 7.8) containing 2 mM EDTA, 1% 
(w/v) SDS and 50 /zg/ml proteinase K. DNA was ex- 
tracted using a procedure to enrich for fragmented DNA 
and electrophoresed on 1.5% agarose gels with 90 mM 
Tris-borate buffer (pH 8.0) containing 2 mM EDTA. DNA 
was visualized by UV illumination after ethidium bromide 
staining. 
3. Results 
Characterization of antibodies. Specificity of the anti- 
bodies was qualitatively examined by dot blot assay using 
peptides-conjugated BSA. Fig. 2 shows the cross-reactivity 
of antisera with various peptides. Peptides were stained 
with antisera from rabbits immunized with the peptides of 
the same sequence. Anti-CFa2 bound to peptides CFa 1, 
CFa2 and V3c~2, the amino termini of which were the 
Anti-CFctl 
Anti-CFct2 
Anti-CF 3 
Anti-CFt 4 
Anti-CTct 
Fig. 2. Specificity of antibodies tosynthetic peptides by dot blot assay. Specificity ofantibodies produced was examined by dot blot assay. Each spot 
contains 100 ng peptide conjug~.ted with BSA. 
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Anti-CTc~ Anti-CFoc2 Anti-CFc~4 
70K- N 42K ~ ~ 
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Fig. 3. Specificity of the antibodies against PKC fragments obtained by proteinase cleavage. PKCo~ was digested with various proteinases (1, none; 2, 
calpain /z; 3, calpain m; 4, trypsin; and 5, chymotrypsin), electrophoresed on 10% polyacrylamide g ls, transferred toPVDF membranes and stained with 
the antibodies. Details are described in Section 2. Digested forms of PKC are indicated by arrowheads. Apparent molecular weights of marker proteins are 
indicated. 
same but they had different carboxyl-terminal stretches. 
Anti-CFa4 also bound to peptide CFa3 that was shorter 
than CFa4 by 13 residues. However, anti-CFa 1 and anti- 
CFa3 very weakly recognized the peptides CFa2 and 
CFa4, respectively, although they had the same amino 
termini. On the other hand, anti-CFa2 did not bind to 
peptide V3 c~ 1 including CFc~ 2 internally. Peptide V3 c~ 2 
harboring the sequence of CFa4 in its carboxyl-terminal 
side was not stained with anti-CFa4. Anti-CFc~2 and 
CFc~4 satisfied requirements for cleavage site-directed an- 
tibodies expected to recognize the amino-terminal regions 
of the catalytic fragments of PKCa. Therefore, these 
antibodies were purified by affinity chromatography on
immobilized peptides, and characterized further by im- 
munoblotting. 
Digestion of PKCa with various proteinases. To exam- 
ine the specificity of antibodies, immunoblot filters were 
prepared where PKC a fragments generated by digestion 
with various proteinases were electrophoresed. As shown 
in Fig. 3, digests were examined by anti-CTc~, antibodies 
against he carboxyl terminal region of PKC a. The digests 
of PKC a by calpains /x and m split into 45- and 46-kDa 
fragments presumably corresponding to the two catalytic 
fragments of different amino-termini (see Fig. 1). Ratios of 
the 45-kDa band to the 46-kDa band generated by diges- 
tion with calpains /x and m were 3:1 and 2:5, respectively, 
when analyzed by anti-CTc~. The 80-kDa PKC was com- 
pletely digested to 45- or 46-kDa fragments. When PKC ce 
was digested with trypsin and chymotrypsin, 45-kDa and 
48-kDa fragments appeared, respectively. 
Characterization of antibodies by immunoblot assay 
using PKCa digests. Purified antibodies were charac- 
terized by immunoblot assay using PKC a digests (Fig. 3). 
Anti-CFc~ 2 and anti-CFa4 specifically stained the 46- and 
45-kDa band, respectively. Furthermore, these antibodies 
did not react with unproteolyzed PKCa which includes 
the same sequences of the peptides used for immunization. 
The 46-kDa band stained with anti-CFa 2 was also found 
Anti-CTc~ Anti-CF(x2 Anti-CFc~4 
93K 
70K 
42K -- 
30K 
20K 
123 123 123 
Fig. 4. Detection of catalytic fragments of PKCot in Ca 2+-ionophore-treated platelets by immunoblotting. Human platelets were treated with ionophore 
A23187 with Ca 2÷ at 37°C for 2 or 5 min, the cytosolic proteins were subjected to PAGE (10% gel) and immunoblotting was performed with the 
antibodies obtained. Untreated (lane 1) and A23187-treated (lane 2, 2 min; lane 3, 5 min) platelets. Digested forms of PKC are indicated by arrowheads. 
Apparent molecular weights of marker proteins are indicated. 
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Fig. 5. DNA fragmentation in serum-free medium treated TIG-3 cells. 
TIG-3 cells were cultured in medium with (lane 1) or without (lane 2) 
fetal bovine serum for 48 h. DNA was prepared from cell lysates, 
electrophresed, and visualized by ethidium bromide staining. Apparent 
molecular weights of marker DNA fragment are indicated left. 
in the trypsin digests of PKCce but not chymotrypsin 
digests. On the other hand, anti-CFc~4 did not react with 
trypsin or chymotrypsin digests of PKC c~. Using diluted 
PKCce digests, it is shown that at least 15 pg of the 
46-kDa and 10 pg of the 45-kDa catalytic fragments could 
be specifically detected by ant i -CFa2 and anti-CFc~4, 
respectively. Moreover, neither ant i -CFa2 nor anti -CFa4 
bound to the catalytic fragment of PKC/3 (data not shown). 
Detection of the catalytic fragment in Ca 2 +-ionophore- 
treated human platelet~ by immunoblotting. Human 
platelets were treated with Ca2+-ionophore A23187 in the 
presence of 2 mM Ca 2+, and fate of PKCc~ in the cytosol 
were determined by immunoblotting using the antibodies. 
A small amount of 45- and 46-kDa PKC a catalytic frag- 
ments together with unproteolyzed PKC ct were detected 
when stained with anti-CTa (Fig. 4). The results indicate 
that Ca 2÷ in the cells mobilized by the ionophore activates 
calpains to cleave PKC a and generated its catalytic frag- 
ments. When analyzed with anti-CFc~2 and anti-CFa4, 
93K . . . .  
70K  , . 
12345678 
<I 
Fig. 6. Activation of calpain m in serum-deprived TIG-3 cells. The whole 
proteins from TIG-3 cells cultured with or without serum for 48 h were 
subjected to SDS-PAGE, electrotransferred to PVDF membranes, and 
stained with the antibody specific to active form of calpain /z [14]. Lane 
1, 0 h; lane 2, 8 h with serum; lane 3, 24 h with serum; lane 4, 48 h with 
serum; lane 5, g h without serum; lane 6, 24 h without serum; lane 7, 48 h 
without serum; lane 8, standard of active form of /z-type calpain. 
Apparent molecular weights of marker proteins are indicated. 
70K 
~;  <z~ ¸ 
iii ill !i!!i!iii!ii!i!iii~iiii~il;!!! 
42K . - -  
1 2 3 
Fig. 7. Generation of the 45-kDa catalytic fragment of PKC a in serum- 
deprived TIG-3 cells. The whole proteins from apoptotic TIG-3 cells 
were subjected to SDS-PAGE followed by immunoblotting, and stained 
with anti-CFa4. Lane 1, standard of the 45-kDa catalytic fragment of 
PKCc~; lane 2, 48 h with serum; lane 3, 48 h without serum. Apparent 
molecular weights of marker proteins are indicated. 
these antibodies pecific for the catalytic fragments, only 
45- and 46-kDa fragments but not the unproteolyzed en- 
zyme were stained, although unproteolyzed PKCa was 
dominant as compared with proteolyzed forms. 
Detection of the catalytic fragment of PKCa in apop- 
totic human fibroblast TIG-3. It has been known that 
treatment of certain cells with serum-free medium causes 
apoptotic cell death [22]. When human fibroblast TIG-3 
cells expressing PKCct abundantly were treated with 
serum-free medium, DNA fragmentation, indicative of 
apoptosis, was observed within 48 h (Fig. 5). We previ- 
ously reported that p-type calpain was activated in the 
apoptotic U937 cells treated with interferon-y/tumor 
necrosis factor-a [14]. Activation of /,-type calpain was 
also observed in the serum-free TIG-3 cells (Fig. 6). 
Moreover, the 45-kDa catalytic fragment was detected in 
the serum-free TIG-3 cells by immunoblotting using anti- 
CFc~4 (Fig. 7). However, the 46-kDa catalytic fragment, a
product generated by calpain m, could not be found in the 
apoptotic fibroblast (data not shown). 
4. Discussion 
In this paper, we have focused on the limited proteoly- 
sis of PKC a by calpains, and developed antibodies that 
discriminate proteolyzed forms. These antibodies obtained, 
in fact, specifically recognized catalytic fragments of 
PKC a but not the unproteolyzed kinase from Ca2+-iono - 
phore treated or apoptotic cells in which the catalytic 
fragments were expected to be generated. Our method in 
which synthetic peptides mimicking the newly generated 
amino-terminal region as the immunogens were utilized 
has made it possible to establish such special antibodies 
without isolation of naturally produced immunogens. The 
antibodies recognized the proteolyzed and unproteolyzed 
polypeptides, the only difference between which is the 
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positive charge of alpha-amino group in the amino termi- 
nus of the newly formed fragment. 
To obtain the antibodies with the desired properties, 
which are called 'cleavage site-directed antibodies' [13,14], 
length of the peptides used for immunogens i  important as 
discussed for conventional nti-peptide antibodies by Van 
Regenmortel t al. [23]. With shorter peptides, antibodies 
raised did not react with the catalytic fragments nor the 
unproteolyzed PKCc~ although they bound to the peptides 
themselves used for immunogens. In fact, anti-CFa I hardly 
bind a longer peptide CFa2 of the same amino terminus. 
On the other hand, when longer peptides were used for 
immunization, antibodies produced recognized both prote- 
olyzed and unproteolyzed PKC ce. These antibodies were at 
least in part a mixture of two types of antibodies; cleavage 
site-directed antibodies that bound the amino terminus of 
the catalytic fragment, and antibodies reacting to both the 
proteolyzed and unproteolyzed PKC a. 
From the above observation, the cleavage site-directed 
antibodies can be obtained alternatively by the following 
two procedures (Fig. 8). One is to synthesize a few short 
peptides with different length of carboxyl-terminal exten- 
sion, and immunize rabbits with them after conjugating 
with carrier proteins (Fig. 8, panel A). Appropriate antisera 
should be selected by dot blot assay and immnoblotting if 
necessary. Another method is to use a longer peptide (e.g., 
15-25 amino acid residue) as an immunogen (Fig. 8, panel 
B). Antibodies thus raised may be a mixture of the cleav- 
A B 
Cleavige site I[ 
a :~- - ]  a / \~  [ 
l Cleavage site 
+ 
I 
Synthesis of a long peptide 
Design of synthetic peptides a  immunogens Generation f anti-peptide antibodies 
II 
1II 
Generation f anti-peptide antibodies 
a b c IV 
 BB- 1 
Selection of the best antisera Pul"ification ofantibodies 
Flow through 
Purification ofcleavage site-directed antibodies bytwo-step affinity chromatography 
Fig. 8. Procedures for obtaining cleavage site-directed antibodies. (A) A few short peptides mimicking the terminal region of proteolyzed fragment of 
interest with different length of carboxyl-terminal extension are synthesized and used as immunogens (I). When antibodies are raised in rabbits (II), 
selection of the best antisera is performed by dot blot assay and/or immunoblotting (Ill). A cleavage site-directed antibodies is purified by affinity 
chromatography using the peptide as a ligand (IV). (B) A longer peptide corresponding to terminal region of proteolyzed fragment is synthesized for an 
immunogen (I). Antibody raised may be a mixture of the cleavage site-directed antibody and antibodies against inner sequences (II). The desirable 
antibody can be obtaind by two-step affinity chromatographies mmobilized with peptides (III). First, antibodies against inner sequence are adsorbed by 
affinity chromatography on an immobilized peptide whose amino terminus is blocked or extended. Finally, the desired antibody is obtained by an affinity 
column with a shorter peptide. 
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age site-directed antibodies and antibodies against inner 
sequences if the peptide is longer than the appropriate 
length for the cleavage site-directed antibody. In such 
cases, the antibody should be purified as follows. When, 
for example, CFc¢4 was used as immunogen, one of four 
rabbits produced only the cleavage site-directed antibody 
and others produced antib,3dies bound to both proteolyzed 
and unproteolyzed PKC o~. From these mixtures, however, 
the desirable antibodies could be obtained by affinity 
chromatographies immobilized with peptides. The proce- 
dures include removal of antibodies against internal region 
by affinity column with V3oz2, which stretched in the 
amino-terminal direction, followed by purification of the 
desired antibodies by an affinity column with a shorter 
peptide (e.g., CFc~3 or CFc~4) as described in Section 2. 
Using this method, we could purify the antibodies pecific 
to the 45-kDa PKC c~ catalytic fragment from anti-CFa4 
antisera containing the antibodies bound to unproteolyzed 
PKC o~ (data not shown). No difference was seen between 
the antibodies prepared from all anti-CFa4 antisera s to 
specificity. We now recommend the second procedure for 
production of a cleavage site-directed antibody (Fig. 8, 
panel B) because delicate design of peptide length for 
immunogens i not required here. Only two or three syn- 
thetic peptides hould be prepared: a longer one for immu- 
nization, a shorter one for purification of antibodies, and, if 
necessary, an amino-terminally blocked or extended one 
for removal of undesired antibodies. 
We previously reported that /z-type calpain is activated 
in apoptotic ells [14]. In this study, the 45-kDa catalytic 
fragment of PKCce was observed in apoptotic human 
fibroblast TIG-3 cell trew:ed with serum-free medium us- 
ing anti-CFce4, while the 46-kDa fragment could not be 
detected using anti-CFa 2. This result is supported by our 
previous finding that only /z-type calpain is activated in 
apoptotic ells. However, further study is needed to deter- 
mine the physiological role of generation of the PKC o~ 
catalytic fragment in the apoptotic human fibroblast. 
Here we establish procedures for production and purifi- 
cation of cleavage site-directed antibodies using synthetic 
peptides corresponding to the proteolyzed sites of a target 
protein. Cleavage site-directed antibodies are useful tools 
for analysis of cellular proteolysis such as phorbol ester-in- 
duced down-regulation f PKC [3] and apoptosis [14]. Our 
method can be applied to in situ immunocytochemical 
studies as well as biochemical analyses on proteases and 
their substrate proteins. 
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